BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Israel scales back use of top missile interceptors as Iran barrages persist - 2Manual for Picking Coastline Travel
- 3Israeli forces kill one person in series of attacks on southern Lebanon
- 4Treasure trove found in Egyptian tomb solves ancient mystery
- 5Verdicts against social media companies carry consequences. But questions linger
- Muslim Brotherhood stole half a billion dollars in Gaza donations, Arab sources reveal
- Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- Productive CRM Programming for Client Relationship The executives
- Pick Your Favored kind of books
- 2024 Moving Styles for Kitchen Redesigns
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- Israel issues notice that Ben-Gurion Airport flights likely restricted until at least April 16
